Remote Ischemic PreConditioning (RIPC)

Remote Ischemic PreConditioning Provides Neuroprotection: A Phase 2, Single Center, Randomized, Double-Blind, Sham-Controlled, Safety and Efficacy Study Evaluating the Use of Remote Ischemic Preconditioning in Patients Undergoing Endovascular Repair of Brain Aneurysms

NCT03814850•Sebastian Koch

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn about protecting the brain from low blood flow (ischemia) with limb preconditioning. From human studies the investigators know that the brain can be protected from dangerous low blood flow by reducing the blood flow to an arm or leg for just a short period of time. This is called limb preconditioning. The investigators are studying the safety and feasibility of preconditioning and their effect of protecting the brain from ischemia in two different groups. This is a Phase 2, randomized, double-blind, sham-controlled, design. Up to 50 male and female patients undergoing elective endovascular repair of unruptured brain aneurysm who are randomized to the remote ischemic preconditioned or sham group will be enrolled. This study consists of one 3-9 month study period for each patient plus up to 14 days for enrollment activities. Subjects are required to return between 3-9 months for end-of-study procedures.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. A diagnosis of an unruptured brain aneurysm deemed suitable for repair by neuroendovascular techniques involving intraluminal occlusion by detachable platinum coils, stent-assisted coiling, pipeline stent, balloon-assisted coiling, covered stent only, neck-bridge device, re-coiling, or re-treatment of a previously coiled/treated aneurysm. There are no restrictions on adjunctive devices.
•2. Absence of ongoing ischemic symptoms such as transient ischemic attacks, minor strokes, stroke-in-evolution, or clinical evidence of cerebral vasospasm within 2 weeks prior to randomization. (If a CT scan, cerebral angiogram, or other imaging performed during the 2 weeks prior to randomization shows radiological vasospasm deemed by the treating physician to be potentially clinically significant, the subject is excluded).
•3. Male or female with a minimum age of 18 years on the day of enrollment.
•4. Informed consent and availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed Informed Consent Form.

Exclusion Criteria

•1. Dissecting or mycotic brain aneurysm. Fusiform or atherosclerotic intracerebral aneurysms may be eligible for the trial if endovascular treatment is planned with a goal of exclusion of the aneurysm from the circulation.
•2. Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment.
•3. Known history of life-threatening allergic reaction to any medication.
•4. Soft tissue, orthopedic, or vascular injury which, in the judgment of the investigator, would preclude arm ischemic conditioning (e.g. superficial wounds, venous, arterial ulcers, gangrene).
•5. History of peripheral vascular disease or deep vein thrombosis in either arm.
•6. Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
•7. Women who are breastfeeding.
•8. Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.
•9. Pre-morbid (estimated) modified Rankin scale score of greater than 2. A subject is not excluded if they have a pre-morbid modified Rankin scale of greater than 2 but the disability does not interfere with the subject's ability to complete an MRI and the cognitive evaluations.
•10. Previous serious traumatic brain injury that would preclude the patient from completing the protocol or preclude MRI analysis of small strokes.
+8 more criteria

Locations (2)

Jackson Memorial Hospital

Miami, Florida, United States

University of Miami

Miami, Florida, United States

Key Dates

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

December 8, 2023

Conditions

Unruptured Cerebral Aneurysm

Interventions

Standard Manual Aneroid Sphygmomanometer

DEVICE

NEUROvascular NAVigation With Remotely Controlled Deflectable Guidewire, Study II (NeuroNAV Study II)

NCT06972966

Unruptured Cerebral Aneurysm

View study

RECRUITING

AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction

NCT06766422

Unruptured Cerebral AneurysmArtificial Intelligence (AI)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 8, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Remote Ischemic PreConditioning (RIPC)

Inclusion Criteria

Exclusion Criteria

NEUROvascular NAVigation With Remotely Controlled Deflectable Guidewire, Study II (NeuroNAV Study II)

AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction

Chinese Small Intracranial Aneurysm Study (CSIAS)

Aspirin Attenuates Inflammation in Human Cerebral Aneurysms